Image: Neurology AdvisorRecent FDA Drug Approvals Rely on Fewer Studies, More Industry Funding - Neurology Advisor
• Researchers conducted a retrospective review of all novel FDA drug approvals from 2016 through 2024 to analyze the evidence used for authorization. • The study used FDA public records and the ClinicalTrials.gov database to track the number of completed trials and their funding sources. • The findings show that novel drug approvals in the US have been supported by a decreasing number of studies since 2016.
neurologyadvisor.com
